Phathom Pharmaceuticals, Inc. (PHAT) Tops Q1 EPS by 9c, provides guidance

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) reported Q1 EPS of ($0.18), $0.09 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $58.3 million versus the consensus estimate of $58.67 million.

GUIDANCE:

Phathom Pharmaceuticals, Inc. sees FY2026 revenue of $320-345 million, versus the consensus of $332 million.
Gross-to-net discount of 55–59%
Gross margin of approximately 80%
Non-GAAP operating expenses, excluding stock-based compensation, of $235–$255 million
Operating profitability, excluding stock-based compensation, expected beginning in the third quarter 2026 and for the full year 2026

For earnings history and earnings-related data on Phathom Pharmaceuticals, Inc. (PHAT) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Reading (RDI) Tops Q2 EPS by 4c